MedPath

Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer

Phase 2
Completed
Conditions
Prostate Cancer Adenocarcinoma
Interventions
Radiation: Hypo-FLAME study
Registration Number
NCT02853110
Lead Sponsor
UMC Utrecht
Brief Summary

The hypo-FLAME study is a multicenter phase II study (n=100) to investigate whether a focal SBRT boost to the MRI-defined macroscopic tumor volume is feasible and associated with acceptable toxicity in addition to whole gland prostate SBRT.

Detailed Description

Rationale: Hypofractionation with a stereotactic body radiotherapy (SBRT) technique for prostate cancer produces excellent treatment outcome in terms of survival and toxicity and is much more convenient than the current fractionation scheme. Local recurrence occurs most frequently at the site of the primary or dominant tumor location prior to treatment. Therefore dose escalation at the site of the primary tumor may improve disease control.

Objective: The main goal of this phase II study is to investigate whether a focal ablative SBRT boost to the macroscopic tumor is feasible and associated with acceptable toxicity in addition to whole gland prostate SBRT. The secondary objectives of this study are: late toxicity, quality of life (QoL) and biochemical disease free survival (bDFS). Furthermore, two side-studies are incorporated in this phase II study: 1) a weekly MRI will be performed to prepare for future MRI-guided (MR-linac) treatment without gold fiducial markers and 2) blood sampling for translational research (radiogenomics) and Biobank purposes.

Study design: Prospective multicenter interventional study on whole gland prostate SBRT using MRI for focal boost in 100 consecutive intermediate or high risk prostate cancer patients.

Study population: One hundred patients with histologically proven prostate adenocarcinoma with intermediate risk or high risk disease. Patients referred for external beam radiotherapy (EBRT) who fulfill the inclusion criteria and without any of the exclusion criteria will be included in the present trial after written informed consent.

Intervention: Patients will be treated by external beam radiotherapy with a SBRT technique with 35 Gy in 5 weekly fractions and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy. In addition, patients will be asked to undergo 5 additional MRI scans (\~15 min/scan) without contrast enhancement prior to each radiation session as well as blood sampling for translational research (radiogenomics) and Biobank purposes.

Main study parameters/endpoints: The primary endpoints of this study are acute gastrointestinal (GI) and genitourinary (GU) toxicity using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Secondary endpoints are late GI and GU toxicity, QoL, and bDFS. Simultaneously, two side-studies will be performed, i.e. to prepare for MRI-guided radiotherapy and blood sampling for translational research (radiogenomics) and Biobank purposes.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
100
Inclusion Criteria
  • Men ≥ 18 years with histologically confirmed prostate adenocarcinoma
  • Intermediate-risk prostate cancer or high-risk prostate cancer, defined as at least one of the following risk criteria: clinical T-stage T2b, T2c or T3a (defined on MRI) or T3b with less than 5 mm invasion in the seminal vesicle, Gleason sum score ≥ 7, PSA ≥ 10 ng/mL
  • Prostate tumor nodule visible on MRI
  • Ability to give written informed consent and willingness to return for follow-up
Exclusion Criteria
  • Prior pelvic radiotherapy, transurethral prostate resection or prostatectomy
  • Unsafe to have gold fiducial marker implantation
  • Contraindications to MRI according to the Radiology Department guidelines (metal implants, non-compatible cardiac device, allergy to Gadolinium, severe renal dysfunction or severe claustrophobia)
  • Evidence of lymph node involvement or distant metastatic disease
  • Clinical T-stage > T3b with ≥ 5 mm invasion in the seminal vesicle
  • World Health Organization (WHO) performance score > 2
  • International prostate symptoms score (IPSS score) ≥ 15
  • PSA > 30 ng/mL

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Hypo-FLAMEHypo-FLAME studyExternal beam radiotherapy, 5 additional MRI scans, blood sampling
Primary Outcome Measures
NameTimeMethod
Acute toxicity90 days after first radiation treatment

The goal of the present study is to investigate whether a focal SBRT boost to the macroscopic tumor is feasible and associated with acceptable toxicity in addition to whole gland prostate SBRT. Toxicity will be assessed by the acute gastrointestinal (GI) and genitourinary (GU) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Acute toxicity is defined as toxicity occurring within 90 days after the first radiation treatment.

Secondary Outcome Measures
NameTimeMethod
Quality of life - prostate specific5 years after last radiation treatment

EORTC QLQ- PR25 questionnaire

Late toxicity10 years after last radiation treatment

Late toxicity, assessed by the late GI and GU Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Late toxicity is defined as toxicity occurring after at least 90 days after the first radiation treatment.

Biochemical disease free survival (bDFS)10 years after last radiation treatment

Biochemical disease free survival

Quality of life - general5 years after last radiation treatment

European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire

Trial Locations

Locations (4)

NKI-AvL

🇳🇱

Amsterdam, Netherlands

UMC Utrecht

🇳🇱

Utrecht, Netherlands

UZ Leuven

🇧🇪

Leuven, Belgium

Radboudumc

🇳🇱

Nijmegen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath